tradingkey.logo

BRIEF-Palatin Completes Phase 2 Obesity Study With Mc4r Bremelanotide Plus Glp-1/Gip Tirzepatide

ReutersFeb 6, 2025 12:33 PM

- Eli Lilly and Co LLY.N:

  • PALATIN COMPLETES PHASE 2 OBESITY STUDY WITH MC4R BREMELANOTIDE PLUS GLP-1/GIP TIRZEPATIDE

  • PALATIN TECHNOLOGIES INC - TOPLINE DATA RESULTS EXPECTED LATER THIS QUARTER

Source text: ID:nPnbyzcCga

Further company coverage: LLY.N

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI